BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 14761977)

  • 1. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.
    Zhang Z; Wang H; Li M; Agrawal S; Chen X; Zhang R
    J Biol Chem; 2004 Apr; 279(16):16000-6. PubMed ID: 14761977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.
    Jin Y; Zeng SX; Sun XX; Lee H; Blattner C; Xiao Z; Lu H
    Mol Cell Biol; 2008 Feb; 28(4):1218-29. PubMed ID: 18086887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
    Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
    J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
    Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
    Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53-Mdm2 module and the ubiquitin system.
    Michael D; Oren M
    Semin Cancer Biol; 2003 Feb; 13(1):49-58. PubMed ID: 12507556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21.
    Nakanishi Y; Pei XH; Takayama K; Bai F; Izumi M; Kimotsuki K; Inoue K; Minami T; Wataya H; Hara N
    Am J Respir Cell Mol Biol; 2000 Jun; 22(6):747-54. PubMed ID: 10837373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p21
    Lee J; Kim J; Kim EM; Kim U; Kang AR; Park JK; Um HD
    Biochem Biophys Res Commun; 2021 Mar; 543():23-28. PubMed ID: 33503543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
    J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
    An WG; Hwang SG; Trepel JB; Blagosklonny MV
    Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.